[Type 1 Gaucher's disease in the adult. Nutritional management during initiation of treatment with miglustat].
Déchelotte
Pierre
P
Unité de nutrition clinique, CHU Rouen, France.
D000328:Adult; D000930:Antidiarrheals; D003131:Combined Modality Therapy; D003967:Diarrhea / Q000139:chemically induced* / Q000178:diet therapy*; D004040:Dietary Carbohydrates / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D004187:Disaccharides / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005632:Fructose / Q000008:administration & dosage; D005772:Gastrointestinal Transit / Q000187:drug effects; D005776:Gaucher Disease / Q000188:drug therapy*; D005960:Glucosides / Q000378:metabolism; D005962:Glucosylceramidase / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008139:Loperamide / Q000008:administration & dosage; D008286:Malabsorption Syndromes / Q000139:chemically induced* / Q000178:diet therapy*; D009005:Monosaccharides / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D019936:Probiotics / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors
D000930:Antidiarrheals; D004040:Dietary Carbohydrates; D004187:Disaccharides; D005960:Glucosides; D009005:Monosaccharides; D011994:Recombinant Proteins; D005632:Fructose; D008139:Loperamide; D005962:Glucosylceramidase; C090568:imiglucerase